Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K243426
    Date Cleared
    2025-03-27

    (143 days)

    Product Code
    Regulation Number
    882.1450
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    Headsafe MFG Pty Ltd

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Nurochek-Pro System is intended for prescription use in healthcare facilities for subjects aged between 12 and 44 years old. for the aid in diagnosis of mild traumatic brain injury (mTBI) in conjunction with a standard neurological assessment.

    The Nurochek-Pro System is indicated for the generation of visual evoked potentials (VEP) and to acquire, transmit, display, and store electroencephalograms (EEG) during the generation of VEPs. Additionally, the system is indicated to analyze captured EEG signals to provide an aid in the diagnosis of mild traumatic brain iniury (mTBI) in subjects aged between 12 and 44 years old who have sustained a potential head injury in the past 120 hours (5 days).

    Device Description

    The Nurochek-Pro System is a portable system designed to generate visual evoked potentials (VEPs) in patients and acquire, transmit, display, and store the resulting electroencephalogram (EEG). It is intended for prescription use in healthcare facilities, by healthcare professionals, on subjects aged between 12 and 44 years old, to aid in the diagnosis of mild traumatic brain injury (mTBI). The primary components of the Nurochek-Pro System are the wearable headset, the Nurochek-Pro Software Application, and the Nurochek-Pro Server.

    AI/ML Overview

    Here's a summary of the acceptance criteria and the study that proves the device meets them, based on the provided text:


    Acceptance Criteria and Device Performance

    Acceptance CriteriaReported Device Performance (Nurochek-Pro System)
    Sensitivity0.8551 (85.51%) with a 95% confidence interval of (0.7496, 0.9283)
    Specificity0.6705 (67.05%) with a 95% confidence interval of (0.5621, 0.7670)
    Positive Predictive Value (PPV)67.0%
    Negative Predictive Value (NPV)85.5%
    Ability to differentiate between subjects with and without mTBI"The study demonstrated that the device can differentiate between subjects with and without mTBI."

    Study Details

    1. Sample size used for the test set and data provenance:

      • Sample Size: 157 individual steady-state visual-evoked potential (SSVEP) readings.
      • Data Provenance: Not explicitly stated, but the study involved "study subjects (age range 12-49 years)" and the clinical research protocol required readings to be collected within 120 hours of suspected head injury, in addition to a clinical evaluation by a licensed physician. This suggests prospective data collection in a clinical setting. The manufacturer is Headsafe MFG Pty Ltd. in Australia, which may imply data origin.
    2. Number of experts used to establish the ground truth for the test set and their qualifications:

      • Number of Experts: Not explicitly stated as a specific number. However, the ground truth was established by "Each highly trained physician". This implies multiple physicians were involved.
      • Qualifications of Experts: "highly trained physician" who used "their education and experience to deliver their mTBI determination." This likely includes neurologists or emergency medicine physicians, given the context of mTBI diagnosis.
    3. Adjudication method for the test set:

      • Adjudication Method: Not explicitly stated if a formal adjudication method (like 2+1 or 3+1) was used. The text mentions "Each highly trained physician used their education and experience to deliver their mTBI determination." This suggests individual clinical determination, but not necessarily a consensus or tie-breaking process.
    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance:

      • MRMC Study: Not explicitly stated that an MRMC comparative effectiveness study was conducted involving human readers with and without AI assistance. The study described focuses on the device's standalone performance against clinical diagnosis.
      • Effect Size: Therefore, no effect size for human reader improvement with AI assistance is provided.
    5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

      • Standalone Performance: Yes, the described performance (Sensitivity, Specificity, PPV, NPV) represents the standalone performance of the Nurochek-Pro System's classification algorithm. The clinical investigation aimed to "evaluate the performance of the Nurochek-Pro System against clinical diagnosis."
    6. The type of ground truth used:

      • Ground Truth Type: Clinical diagnosis by a licensed healthcare professional. This diagnosis was based on "a neurological examination, a concussion-related signs and symptom evaluation, and a review of all relevant information provided by the study subject in relation to their injury."
    7. The sample size for the training set:

      • Sample Size: 272 individual steady-state visual-evoked potential (SSVEP) readings.
    8. How the ground truth for the training set was established:

      • Training Set Ground Truth: The text states, "The Headsafe classification Algorithm used in this device was generated with 272 individual steady-state visual-evoked potential (SSVEP) readings, in which there was a 24.6% prevalence of mTBI." While not explicitly detailed for the training set ground truth establishment, it can be inferred that a similar process involving clinical evaluation by licensed physicians (as described for the validation set) was used to establish the mTBI status for the cases used to generate the algorithm. The "clinical research protocol required readings to be collected within 120 hours of the suspected head injury, in addition to a clinical evaluation by a licensed physician" applies to the study subjects from which the database was generated.
    Ask a Question

    Ask a specific question about this device

    K Number
    K231914
    Date Cleared
    2023-12-27

    (181 days)

    Product Code
    Regulation Number
    882.1450
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    Headsafe MFG Pty Ltd

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Nurochek-II System is intended for prescription use in healthcare facilities for subjects aged between 16 and 46 years old, for the aid in diagnosis of mild traumatic brain injury (mTBI) in conjunction with a standard neurological assessment.

    The Nurochek-II System is indicated for the generation of visual evoked potentials (VEPs) and to acquire, transmit, display, and store electroencephalograms (EEGs) during the generation of VEPs. Additionally, the system is indicated to analyze captured EEG signals to provide an aid in the diagnosis of mild traumatic brain injury (mTBI) in subjects aged between 16 and 46 years old who have sustained a potential head injury in the past 72 hours (3 days).

    Device Description

    The Nurochek-II System is a portable system designed to generate visual evoked potentials (VEPs) in patients and acquire, transmit, display, and store the resulting electroencephalogram (EEG). It is intended for prescription use in healthcare facilities for subjects aged between 16 and 46 years, to aid in the diagnosis of mild traumatic brain injury (mTBI). The primary components of the Nurochek-II System are the wearable headset, the Nurochek-II software application, and the Nurochek-II server.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study details for the Nurochek-II System:

    1. Table of Acceptance Criteria and Reported Device Performance

    The FDA 510(k) summary does not explicitly state "acceptance criteria" for sensitivity and specificity in a separate section. However, it presents the performance of the Nurochek-II System and compares it to a predicate and reference device, implying these metrics are key for demonstrating substantial equivalence. Given the context, the performance metrics reported for the Nurochek-II System are the results of its performance against a clinical diagnosis.

    MetricAcceptance Criteria (Implied by reported performance for Nurochek-II System)Reported Device Performance (Nurochek-II System)
    Sensitivity (95% CI)Achieved 86.05% (72.07-94.70)86.05% (72.07-94.70)
    Specificity (95% CI)Achieved 67.16% (54.60-78.15)67.16% (54.60-78.15)
    Positive Predictive Value (PPV) (95% CI)Achieved 62.7% (53.92-70.75)62.7% (53.92-70.75)
    Negative Predictive Value (NPV) (95% CI)Achieved 88.2% (77.79-94.13)88.2% (77.79-94.13)

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size for Test Set: 110 individual Steady-State Visual-Evoked Potential (SSVEP) readings.
    • Data Provenance: The document does not explicitly state the country of origin. However, the manufacturer, Headsafe MFG Pty Ltd., is based in Surry Hills, NSW, Australia, suggesting the study may have been conducted in Australia or related clinical sites.
    • Retrospective or Prospective: The study is described as a "clinical investigation" with a "clinical research protocol" and the collection of readings within 72 hours of suspected head injury, followed by a clinical evaluation. This indicates a prospective study design.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

    • Number of Experts: Not explicitly stated as a specific number. The document mentions "Each highly trained physician." This phrasing suggests multiple physicians were involved, but the exact count is not provided.
    • Qualifications of Experts: "Highly trained physician" using "their education and experience to deliver their mTBI determination." This included a neurological examination, a concussion-related signs and symptom evaluation, and a review of all relevant information provided by the study subject.

    4. Adjudication Method for the Test Set

    The document does not explicitly describe a formal adjudication method (e.g., 2+1, 3+1). It states that "Each highly trained physician used their education and experience to deliver their mTBI determination." This implies that the individual physician's diagnosis served as the ground truth without a stated consensus or adjudication process among multiple ground truth experts for each case.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

    No, a multi-reader multi-case (MRMC) comparative effectiveness study was not explicitly described. The study focuses on the standalone performance of the Nurochek-II System against a clinical diagnosis. There is no information provided about human readers improving with AI vs. without AI assistance.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

    Yes, a standalone performance study was done. The reported sensitivity, specificity, PPV, and NPV are for the Nurochek-II System's classification algorithm in differentiating between subjects with and without mTBI, based solely on the analysis of captured EEG signals.

    7. The Type of Ground Truth Used

    The ground truth used was expert clinical diagnosis. This was established by "a licensed healthcare professional" (a "highly trained physician") based on a standard neurological assessment, a concussion-related signs and symptom evaluation, and a review of relevant patient information.

    8. The Sample Size for the Training Set

    The classification algorithm was "generated with 372 individual steady-state visual-evoked potential (SSVEP) readings." This indicates that the training set consisted of 372 individual SSVEP readings.

    9. How the Ground Truth for the Training Set Was Established

    The ground truth for the training set was established through the same method as the test set: a clinical evaluation by a licensed physician. The protocol required readings to be collected within 72 hours of suspected head injury, in addition to a clinical evaluation by a licensed physician. Their determination was based on a neurological examination, a concussion-related signs and symptom evaluation, and a review of all relevant information.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1